Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a...

Area of Science:

• Hematology
• Transfusion Medicine
• Immunology

Background:

• Alloimmunization is a significant risk in platelet transfusion recipients.
• Pathogen-reduction treatment aims to mitigate transfusion-transmitted infections and potentially reduce alloimmunization.
• Understanding the efficacy of pathogen-reduction systems in preventing alloimmunization is crucial for patient safety.

Purpose of the Study:

• To evaluate whether pathogen-reduction treatment of platelet components reduces the risk of human leukocyte antigen (HLA) alloimmunization in patients with hematologic cancer.
• To compare alloimmunization rates between patients receiving pathogen-reduced platelets and those receiving conventional platelets.

Main Methods:

• Two parallel, randomized clinical trials were conducted, comparing Mirasol or Intercept pathogen-reduction systems against conventional platelets.
• 179 patients per arm with hematologic cancer were included, with baseline and follow-up samples analyzed.
• HLA antibody levels were measured using a commercial multianalyte, bead-based assay.

Main Results:

• The rate of HLA Class I alloimmunization was low in conventional platelet recipients (1.2%-5.9%).
• No statistically significant difference in alloimmunization rates was observed between pathogen-reduced and conventional platelet groups.
• A potential protective effect, though not statistically significant, was suggested for high-level HLA Class I antibodies with Intercept treatment.

Conclusions:

• The study was underpowered to definitively conclude on the protective effect of pathogen-reduction treatment against HLA alloimmunization.
• The findings provide valuable data for designing future, adequately powered trials to assess this protective effect.
• Further investigation is warranted to establish the role of pathogen-reduction technology in preventing alloimmunization during platelet transfusions.